Xynomic Pharmaceuticals, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2018
NCT03592472
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Xynomic Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Renal Cell (Phase 3)

Carcinoma, Squamous Cell (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 1)

Neoplasms (Phase 1)

Skin Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Ureteral Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 9